Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer

HER2-overexpression in tumor tissue is observed in 6 to 23% of advanced gastric cancer (GC) cases, and trastuzumab is an active molecular drug for these patients. There are no data available on whether serum levels of ligands are associated with the response and resistance to trastuzumab in HER2-pos...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Takahashi, Naoki, Furuta, Koh, Taniguchi, Hirokazu, Sasaki, Yusuke, Shoji, Hirokazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Hamaguchi, Tetsuya, Shimada, Yasuhiro, Yamada, Yasuhide
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2015
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826254/
https://ncbi.nlm.nih.gov/pubmed/26716644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6753
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak